secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001193125-22-003165
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction
--------------------------------------------------------------------------------

- Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.
- Phase 1 study showed no meaningful HBsAg reduction at projected efficacious dose of 400 mg.
- Higher doses up to 600 mg unlikely to reach 1 log10 IU/mL HBsAg reduction threshold.
- No dose-limiting safety findings; decision made jointly with Study Review Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/0001193125-22-003165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/d288360d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-003165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer